Norway: Nordic Nanovector replaces CEO as part of restructuring

Oslo-listed Nordic Nanovector, a developer of therapies to address major unmet medical needs and advance cancer care, has consolidated its senior leadership team following the decision to discontinue the PARADIGME study for its lead asset Betalutin and restructure the company. The consolidation sees current CEO Erik Skullerud transition out of his role while CFO, Malene…

You must be a HMI Subscriber to view this content.

Subscribe Now »